No benefit from addition of aliskiren to 'gold standard' ACE inhibitor
Monday, April 4, 2016 - 22:10
in Health & Medicine
In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported.